Pacer Funds Trust Pacer PE/VC ETF (ARCA: PEVC)

Últimas noticias sobre Pacer Funds Trust Pacer PE/VC ETF (ARCA:PEVC)

Technology

Financial Services

Communication Services

Consumer Cyclical

Industrials

Healthcare

Consumer Defensive

Energy

Basic Materials

Utilities

Real Estate

Other

The Fund employs a passive management (or indexing) investment approach designed to track the total return performance, before fees and expenses, of the Index. The Index is based on a proprietary methodology developed and maintained by the FTSE Russell Group (the Index Provider). For both of the FTSE PE (Buyout) and VC indices, there is both a benchmark index (each, a Benchmark Index) and a tracking or investable Index. The FTSE PE Buyout Benchmark Index includes nearly 5,400 private equity- backed companies with a total value of nearly $5 trillion. The FTSE VC Benchmark Index includes over 13,000 venture capital backed companies valued at over $2.5 trillion. Both Benchmark Indices have specific investable indices that seek to track the performance of the FTSE Benchmark Indices through portfolios of liquid assets using proprietary econometric models. These tracking indices, the FTSE Private Equity Buyout Index and the FTSE Venture Capital Index, are both available on Bloomberg with daily pricing (tickers: TRPEI and TRVCI). The Index is a rules-based index that aims to provide exposure to a portfolio that mimics the returns of a theoretical investment in a diversified pool of private equity and venture capital-backed companies. The Index is comprised of varying weights to the FTSE Private Equity Buyout Index (the Buyout Index) and the FTSE Venture Capital Index (the VC Index). The Buyout Index weight will be set at a range of 50 percent to 95 percent, with the balance allocated to the VC Index. The Indexs relative weights to the Buyout Index and VC Index are determined at each calendar month-end based on optimal relative weighting over recent time periods. The Index is calculated and published daily.

Meta Platforms, Inc.

Microsoft Corp

Alphabet Inc

Visa Inc

Mastercard Inc

Netflix, Inc.

Berkshire Hathaway, Inc.

Apple Inc

Nvidia Corp.

Amazon.Com Inc

Oracle Corp.

Palantir Technologies Inc.

Pacer PE/VC ETF

Pacer Funds Trust Pacer PE/VC ETF

Morgan Stanley analyst Dara Mohsenian maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and lowers the price target from $150 to $137.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Clorox, Lowers Price Target to $137

Morgan Stanley analyst Toni Kaplan maintains Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) with a Underweight and raises the price target from $100 to $104.

BFAM

Morgan Stanley Maintains Underweight on Bright Horizons Family, Raises Price Target to $104

WIIM

FIVN

FIVN stock has given up its prior gain. Five9 shares were trading higher after the company reported better-than-expected Q2 financial results, issued Q3 adjusted EPS guidance above estimates, and raised its FY25 guidance.

Guggenheim analyst John Difucci maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Sell and raises the price target from $70 to $111.

Guggenheim Maintains Sell on Cloudflare, Raises Price Target to $111

Morgan Stanley analyst Stephen Byrd maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Overweight and raises the price target from $35 to $44.

Morgan Stanley Maintains Overweight on Bloom Energy, Raises Price Target to $44

TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) reported quarterly earnings of $0.43 per share. This is a 95.45 percent increase over earnings of $0.22 per share from the same period last year. The company reported $3.589 billion in sales this quarter. This is a 7.81 percent increase over sales of $3.329 billion the same period last year.

Earnings

TTDKY

TDK Q1 EPS $0.43 Up From $0.22 YoY, Sales $3.589B Up From $3.329B YoY

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $146 to $144.

BIIB

Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $144

Wells Fargo analyst Larry Biegelsen maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Equal-Weight and lowers the price target from $137 to $131.

Wells Fargo Maintains Equal-Weight on Teleflex, Lowers Price Target to $131

AAPL

AAPL stock has given up its prior gain. Apple shares were trading higher following better-than-expected Q3 financial results.

Morgan Stanley analyst Patrick Wood maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Equal-Weight and raises the price target from $12 to $13.

BLCO

Morgan Stanley Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $13

Cantor Fitzgerald analyst Steve Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Overweight and raises the price target from $39 to $40.

APLS

Cantor Fitzgerald Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $40

Wells Fargo analyst Larry Biegelsen maintains Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) with a Equal-Weight and lowers the price target from $6 to $3.

LUNG

Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $3

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Overweight and raises the price target from $700 to $766.

ARGX

Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $766

Wells Fargo analyst Larry Biegelsen maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Equal-Weight and lowers the price target from $33 to $24.

Wells Fargo Maintains Equal-Weight on Baxter Intl, Lowers Price Target to $24

Morgan Stanley analyst Bob Huang maintains Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) with a Overweight and raises the price target from $235 to $245.

Morgan Stanley Maintains Overweight on Allstate, Raises Price Target to $245

Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) reported quarterly earnings of $2.46 per share which beat the analyst consensus estimate of $2.42 by 1.61 percent. This is a 14.42 percent increase over earnings of $2.15 per share from the same period last year. The company reported quarterly sales of $587.300 million which beat the analyst consensus estimate of $574.025 million by 2.31 percent. This is a 14.31 percent increase over sales of $513.800 million the same period last year.

Earnings Beats

CBOE

CORRECTION: Cboe Global Markets Q2 Adj. EPS $2.46 Beats $2.42 Estimate, Sales $587.300M Beat $574.025M Estimate

Cantor Fitzgerald analyst Troy Jensen maintains Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Overweight and raises the price target from $50 to $51.

PRLB

Cantor Fitzgerald Maintains Overweight on Proto Labs, Raises Price Target to $51

Morgan Stanley analyst Joseph Moore maintains Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Equal-Weight and lowers the price target from $38 to $35.

ALGM

Morgan Stanley Maintains Equal-Weight on Allegro Microsystems, Lowers Price Target to $35

Wells Fargo analyst Finian O'Shea maintains Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) with a Overweight and raises the price target from $21 to $24.

TSLX

Wells Fargo Maintains Overweight on Sixth Street Specialty, Raises Price Target to $24

Morgan Stanley analyst Joseph Moore maintains Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) with a Equal-Weight and raises the price target from $11 to $19.

Comments

Pacer Funds Trust Pacer PE/VC ETF

Noticias

Últimas noticias sobre Pacer Funds Trust Pacer PE/VC ETF (ARCA:PEVC)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL